Chandra Vargeese, Ph.D., is a distinguished scientist and executive who currently holds the position of Chief Technology Officer and Head of Platform Discovery Sciences at WAVE LIFE SCIENCES LTD. Dr. Vargeese's career is marked by significant contributions to the fields of biotechnology and pharmaceutical research. She earned her Ph.D. in Organic Chemistry from the University of Notre Dame, which laid the foundation for her expertise in nucleic acid chemistry and drug discovery. Throughout her career, Dr. Vargeese has held pivotal roles in several leading organizations. Prior to joining WAVE LIFE SCIENCES LTD, she served as the Vice President of Drug Discovery at Moderna Therapeutics, where she played a crucial role in advancing mRNA-based therapeutics. Her work at Moderna was instrumental in the development of innovative treatments that have the potential to transform patient care. Dr. Vargeese's extensive experience also includes significant contributions at Sirnaomics, where she led the development of RNAi-based therapeutics, and at Merck, where she focused on oligonucleotide chemistry and drug discovery. In her current role at WAVE LIFE SCIENCES LTD, Dr. Vargeese is responsible for steering the company's technology strategy and leading the discovery sciences platform. Her leadership is vital in advancing WAVE's proprietary PRISM platform, which is designed to develop novel genetic medicines for a wide range of diseases. Under her guidance, the company continues to push the boundaries of RNA-targeted therapies, aiming to bring transformative treatments to patients with serious, genetically defined diseases. Dr. Vargeese's strategic vision and scientific expertise are pivotal in driving WAVE LIFE SCIENCES LTD towards its goal of revolutionizing precision medicine.